Nov 11, 2021 | 2021, Investors, Press Releases
Press Release 11-11-2021Nov 8, 2021 | 2021, Past Events
Dr. Tobias Weiss, the Principal Investigator of Fibromun’s programs in brain tumors, is presenting an ePoster entitled “Lomustine and targeted-cytokine therapy: a beneficial liaison for recurrent glioblastomaNov 7, 2021 | 2021, Past Events
Philogen is presenting a ePoster on the results of the run-in part of the Phase II study with Fibromun plus Dacarbazine for patients with in third or later line advanced/metastatic soft tissue sarcoma. See here for more details.Nov 6, 2021 | 2021, Past Events
Philogen announces its attendance at the Festival of Biologics Basel on November 10, 2021 Lisa Nadal, 3-year PhD student at Philogen, is giving a lecture entitled “A novel IL12-based immunocytokine targeting Fibroblast Activation Protein (FAP) for the treatment...Nov 4, 2021 | 2021, Past Events, Scientific
Dario Neri, co-founder, CEO and CSO, is giving a presentation to address the question on how to achieve the therapeutic dose at the tumor site with cytokine-based targeted products. Roberto De Luca, Head of Antibody Therapeutics at Philogen, is also giving a...Nov 3, 2021 | 2021, Past Events
Dario Neri, co-founder, CEO and CSO, is giving a presentation focused on Tripokin, a novel fusion protein capable of an exceptionally selective uptake at the tumor site. The product contains two highly synergistic cytokine moieties (interleukin-2 and tumor necrosis...
Recent Comments